Kenvue Inc.
Kenvue Initiates Restructuring and Reports Q1 2024 Results
Summary
Kenvue Inc. announced a multi-year restructuring initiative to optimize its cost structure, aiming for a net global workforce reduction of approximately 4% and annualized pre-tax gross cost savings of $350 million starting in fiscal year 2026. This initiative is expected to result in restructuring expenses and other charges totaling approximately $550 million across fiscal years 2024 and 2025. Additionally, the company released its financial results for the fiscal first quarter ended March 31, 2024.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement